GALECTIN THERAPEUTICS INC — Director's Dealing 2026

Jan 5, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2025-12-31

Reporting Person: Jamil Khurram (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-31	Common Stock	M	8125	$1.23	Acquired	8125	Direct
2025-12-31	Common Stock	S	8125	$4.0725	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-31	Stock option (right to buy)	$1.23	M	8125	Disposed	2035-01-23	Common Stock (8500)	Direct

Footnotes

F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.

F2: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.15. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F3: The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.